Ligand validation:6GR2

GAL: beta-D-galactopyranose

GAL is a Ligand Of Interest in 6GR2 designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
6GR2_GAL_A_401	63%	57%	0.149	0.945	0.67	0.97	-	1	0	0	100%	1
6GR2_GAL_E_401	59%	58%	0.16	0.943	0.64	0.97	-	1	0	0	100%	1
6GR2_GAL_D_401	56%	58%	0.169	0.94	0.64	0.96	-	1	0	0	100%	1
6GR2_GAL_H_401	55%	59%	0.143	0.912	0.6	0.96	-	1	0	0	100%	1
6GR2_GAL_F_401	52%	59%	0.167	0.926	0.6	0.95	-	1	0	0	100%	1
6GR2_GAL_G_401	51%	58%	0.165	0.92	0.65	0.97	-	1	1	0	100%	1
6GR2_GAL_C_401	50%	58%	0.133	0.882	0.66	0.94	-	1	1	0	100%	1
6GR2_GAL_B_401	30%	59%	0.197	0.862	0.63	0.95	-	1	0	0	100%	1
6ZGY_GAL_A_401	89%	24%	0.067	0.946	0.75	2.34	-	2	1	0	100%	1
6Q91_GAL_A_401	88%	20%	0.103	0.98	0.79	2.55	-	5	0	0	100%	1
6Q8Z_GAL_A_401	87%	4%	0.089	0.961	2.28	3.19	6	6	0	1	100%	1
6ZGX_GAL_E_401	86%	11%	0.095	0.962	0.93	3.15	-	5	0	0	100%	1
7OZX_GAL_B_401	81%	34%	0.108	0.959	0.74	1.85	-	2	1	0	100%	1
4WWH_GAL_A_401	100%	64%	0.026	0.99	0.47	0.9	-	-	0	0	100%	1
5ELB_GAL_C_202	100%	58%	0.036	0.992	0.82	0.8	-	-	0	0	100%	0.6
3OGR_GAL_A_1024	99%	47%	0.053	0.987	0.79	1.26	-	1	1	0	100%	1
1NSX_GAL_B_2400	98%	50%	0.055	0.981	0.56	1.36	-	3	0	0	100%	1
4LKF_GAL_A_201	98%	55%	0.045	0.984	0.92	0.83	-	-	0	0	92%	0.9167

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.